In recent years, the World Health Organization listed Psoriasis as a serious public health concern with at least 100 million individuals affected worldwide. Psoriasis a chronic autoimmune skin disease that speeds up the growth cycle of skin cells, producing scales. Inflammation and redness, develop around the scales, which often crack and bleed. This condition may be triggered by environmental and genetic factors. Changing lifestyles of people are leading to increased alcohol consumption and smoking, unhealthy diet, and sedentary living, which make people more prone to this condition. Everyone is at potential risk – even you.
An International Federation of Psoriasis Association report indicates roughly 5.0% of people are afflicted with one or more forms of Psoriasis worldwide. Nearly 7.5 million people are affected by this condition in the U.S. alone. These patients represent approximately 2.0% of the population. Moreover, at least 100,000 new cases are registered and reported every year. A GrandViewResearch Report estimates the global Psoriasis drugs market size was valued at $11.3 billion in 2016. It is anticipated to post a compounded growth rate of 9.4% during the forecast period. A recent report by Transparency Market Research on the global Psoriasis treatment market estimates that it will attain a worth of U.S. $12.1 billion by 2024. Increasing awareness regarding treatment and rising demand for improved healthcare infrastructure are among the primary growth stimulants for the market. This rising incidence of Psoriasis is fueling demand globally for innovative viable treatments.
There is no permanent cure and current treatments only relieve the symptoms of these diseases. Treatments aim to reduce inflammation and scales, slow the growth of skin cells, and remove plaques. Topical ointments (creams) and drugs are the common treatment. The high cost of Psoriasis treatments, extensive drug development, and approval process are hindering the growth of global Psoriasis drugs market.
Perhaps the Biotech companies and FDA are not looking in the right spot. Many feel the drug companies want us to stay sick so they can keep profiting. Imagine there was a natural solution to these dreaded diseases. Picture a world where one compound could treat this and multiple diseases with minimal side effects. Wouldn’t that be amazing?
This Company Could Be The Answer
With its unique products in the pipeline and novel class of Cannabis-based medical products and treatments – OWC Pharmaceutical Research Corp (OTCQB: OWCP)–is in a highly attractive spot to become a leader in this industry.
OWC Pharmaceutical Research Corp conducts medical research and clinical trials to develop and improve strains of medical cannabis, specifically designed for the treatment of several illnesses/medical conditions including multiple myeloma, migraine headaches, fibromyalgia, and Psoriasis. This is accomplished via wholly-owned Israeli subsidiary, One World Cannabis Ltd. Their vision is to become a leader in creating new cannabis-related treatments and devices.
The company entered into an agreement with Mediq Innovation Partners for marketing OWC’s topical Psoriasis cream in Germany. Germany presents a unique sales opportunity given that the country previously legalized medical marijuana use. The legislation provides for the reimbursement of medical cannabis by healthcare facilities in the country. This should pave the way for OWCP to pursue new opportunities across Europe.
OWCP has made significant progress using specific dosages of its Cannabinoid-based products administered through soluble pills taken orally, with its initial focus on PTSD, multiple myeloma andtopical treatment of burns in addition to Psoriasis. Their business model includes collaborative ventures with major medical centers and highly regarded researchers in Israel. They are licensed by the Medical Cannabis Unit of the Israeli Health Ministry.
OWCP’s goal is to improve patients’ quality of life by developing novel therapeutic methods for the treatment of serious medical conditions using cannabis-based therapies. They are conducting pre-clinical investigations and randomized, placebo-controlled trials of cannabis-based compounds and developing unique, condition-specific products.
There have been numerous studies demonstrating the therapeutic value of cannabis, including a comprehensive research review from the National Academies of Sciences, Engineering and Medicine (NASEM). The 395-page report found conclusive evidence that cannabis and its cannabinoids are beneficial for treating symptoms like chronic pain, nausea and vomiting, and spasticity.
OWCP maintains a competitive edge being based in Israel. They are one of the few countries globally which approves Cannabis clinical studies. It seems like the State of Israel inhaled something and woke up as the state of medical cannabis. It is a unique nexus thanks to its expertise in advanced agricultural technologies, in research on the effect of cannabis on the human body, and in drug delivery – an area that the Israeli pharmaceutical industry has specialized in because it requires shorter development times and more inter-disciplinary thought than classic pharmaceuticals. Another area that Israel specializes in is medical equipment.
An Israeli government committee approved the first draft law on the export of medical cannabis, an important step toward the government’s long-delayed plan to foster a medical marijuana export industry. OWCP could benefit from this arrangement.
One of these products being developed is atopical cream which is indicated for different skin diseases, but the initialindication is showing tremendous promise towards Psoriasis. The cream can besold and purchased worldwide – in countries and US states that have legalized the use of Marijuana for medical purposes.
Results From Clinical Trial
OWCP reported initial results from a clinical trial evaluating the cannabinoid-based topical cream for the treatment of Psoriasis. According to the results, the cream led to a 70 percent improvement in Psoriasis-related inflammation parameters. Based on the promising study data, the company is expanding the size and scope of its clinical trial. They received the first-ever Institutional Review Board approval to commence a safety study for a cannabis-based topical cream with more than 3% THC. The company is currently conducting a safety study for the cream in one of the biggest academic hospital in Israel. Completion of the cannabis safety study will be in Q4 ’ 2018 however the initial results are astounding!
- Preclinical studies showed significant reduction of Psoriasisbiomarkers (IL-8 and IL-33) and reduction in keratinocytes.
- Phase I safety study will be completed atSheba Hospital, Tel Hashomer soon.
- Phase II initiation planned for Q1-Q2/2019.
- TLR Phase II estimated Q1/2020.
The Product is fully developed without indication label
OWCP filed a patent application for its active cannabinoid-based topical cream. The patent application, when approved, could accelerate the ongoing discussions and negotiations regarding scientific and medical collaboration. The filling of the patent could potentially allow the company to engage in serious discussion with potential customers and partners regarding the requirements needed for manufacturing of the cream.
The company has also been granted a patent in Australia of the use of its proprietary cream on the treatment of skin orders. The approval marks yet another important milestone as the company continues to strengthen its IP portfolio.
Ground Breaking New Delivery System
OWCP previously announced it completed the development of a proprietary, cannabinoid-enriched sublingual tablet to easily ingest medical cannabis, with fast and effective absorption. They have been working on a new delivery system that would make medical marijuana easier for doctors to administer. The company developed a cannabis tablet which allows doctors closely monitor dosage, unlike current methods such as smoking and ingesting edibles. This tablet will be a substitute for patients being treated with medical cannabis by smoking. Key indications will include chronic pain syndromes and Fibromyalgia, inter alia.
The technology behind the Oral Disintegrating Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through oral epithelial tissue.
Initial study results are VERY promising.
- First generation formulation is fully developed
- Second generation formulation development was completed
- Phase I safety study completion expected Q1/2019 at Tel Aviv Sourasky Medical Center
- May also function as a smoking/inhalation substitute
In December 2017, OWCP announced they received a new permit from the Israeli Medical Cannabis Agency (IMCA) to proceed with safety studies for their proprietary cannabis soluble tablet delivery system. They concurrently received Institutional Review Board (IRB) approval from the Sourasky Medical Centerin Tel Aviv and from the central Israeli Review Board to conduct these studies.
OWCP is also making progress on a nasal spray which could potentially treat Fibromyalgia and PTSD. Their products are in various states of study.
BREAKING NEWS: OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy
OWCP developed a cannabinoid-based drug therapy that was shown to be effective in fighting multiple myeloma cells. In clinical trials, a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) was able to decrease the survival of cancerous cells, a big step for the medical marijuana community.
Multiple myeloma is a cancer of plasma cells in bone marrow and its sufferers make up one percent of cancer patients around the world. The disease is responsible for two percent of the world’s cancer-related deaths.
The company’s first basic study had promising results against the cancerous cells, and OWCP is planning to submit those results for an institutional board review. If approved, the company plans to explore how different CBD and THC combinations can help improve the quality of life for patients suffering from multiple myeloma cancer.
- Designed to be an Orphan
Disease study approved by the FDA
- In-vitro study: Cannabis kills the MM cancer cells
- Initial pre-clinical study on mice: calibration phase for dosage, optimization of ratio of active cannabinoids THC:CBD
- In-vitro study for a combination of cannabis with 4 approved drugs showed promising results
- Next steps: Pre-clinical study for the most effective combination on mice with new cannabis extracts
- SUBJECT TO ACHIEVING RESEARCH MILESTONES, THE COMPANY WILL SUBMIT AN APPLICATION TO THE FDA FOR AN ORPHAN DISEASE DESIGNATION
OWCP fileed a patent application with the United States Patent and Trademark Office for its active cannabinoid-based topical cream. OWCP’s Intellectual Property Portfolio comprises 9 patent families and includes filings in selected domains at various stages from PCT filings, National Phase filings and Continuations in Part (CIP).
They have taken action to protect their Intellectual Property by filing patent applications with the European Union and US Trademark Office. This creates tremendous intrinsic value in the company. Currently they have acquired:
- 9 patent families
- 31 patent filings in selected domains at various stages from PCT filings, National Phase filings and Continuations in Part (CIPs)
- 2 of the patent families are in the field of Multiple Myeloma
- 7 patent families are in the fields of pharmaceutical emulsions, Fibromyalgia, Migraine, Sexual Function and Skin Disorders
Are The Company’s Patents Valued More Than The Company?
OWCP trades at a tiny market cap of just over $22MM. I’ve seen companies in the initial stages of entrance to the MJ markets trading at larger premiums than this. OWCP could potentially be considered undervalued, relative to many of its peers.
Their recently quarterly report, the 10Q, shows they have over $4.3MM in cash, equivalents, and assets on the books. The ENTIRE market cap of OWCP is trading at less than 5x that. What do you think happens when Wall Street discovers they overlooked this potential gem?
OWCP has a number of things going for them. As an innovative developer of Cannabis-based medical and pharmaceutical products,they are centered in Israel – the world leading center for Cannabis research and clinical trial capability.
Their growing intellectual property portfolio potentially protects them from competitors trying to steal their research and apply it for themselves. In the past, Teva Pharmaceuticals made an offer to purchase the rights to the company’s patents. Wouldn’t it make more sense now to just buy them outright?
Most importantly, OWCP has defined development pathways including medicinal and pharmaceutical products, some of which may be ready for market shortly. All of these products in the pipeline provide for some short term catalysts, as corporate updates should be due shortly. With everything Marijuana related going gangbusters, OWCP stands above many peers trading at higher valuations, as a company with both vision and real products.
What do you think will happen if OWCP obtains FDA approval to market in the US, in addition to creating a presences overseas? While that might be years away, Wall Street is just learning about this company. Between the miniscule market cap and recent large-scale visibility on the release of breakthrough medical marijuana products, this could evolve into one of the best investment opportunities of the year. Don’t let it pass you by.
GENERAL NOTICE AND DISCLAIMER – PLEASE READ CAREFULLY. We are engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any company mentioned here. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Owners and operators have been compensated sixteen thousand dollars cash via bank wire, earned upon receipt, for the distribution of our opinions and publicly available information for OWCP by Hanover Financial Services on 11/21/18. By your subscription to our website, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer which can be read at any time at www.SmallCapStocks.com/Disclaimer.